CSL delivers solid first-half financials, but guidance disappoints
Australian plasma fractionation specialist CSL Limited (ASX: CSL) has today announced a net profit after tax (NPAT) of $692 million (all figures in US dollars) for the six months ended December 31, 2014, up 7% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 10% to $1.46.
Sales for the period rose 7% to $2.74 billion, or 8% higher at constant currency. Earnings before interest and taxes (EBIT)$878 million, up 7% on PCP and 9% at constant currency
CSL managing director Paul Perreault said that, in addition to a solid half year the company has continued to invest in future growth with research and development investment increasing to $233 million.
Acquisition of Novartis flu vaccine business
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze